Hutchmed shares slide as recalls cancer treatment Tazverik
9th Mar 2026 10:49
(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen SA. Read More
| Price | 215.00p on 13-03-2026 at 13:38:26 |
|---|---|
| Change | 6.00p 2.87% |
| Buy | 218.00p |
| Sell | 215.00p |
| Last Trade: | Sell 2.00 at 215.00p |
| Day's Volume: | 7,427 |
| Last Close: | 209.00p |
| Open: | 219.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 215.00p - 219.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.85b |
| VWAP: | 215.28416p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 2 | 215.00p | SI Trade |
13:36:10 - 13-Mar-26 |
| Buy* | 2 | 218.00p | SI Trade |
13:36:10 - 13-Mar-26 |
| Sell* | 150 | 215.20p | Ordinary |
12:48:14 - 13-Mar-26 |
| Sell* | 150 | 215.15p | Ordinary |
12:20:23 - 13-Mar-26 |
| Unknown* | 0 | 215.00p | SI Trade |
12:20:16 - 13-Mar-26 |
| Unknown* | 0 | 215.00p | SI Trade |
12:20:16 - 13-Mar-26 |
| Sell* | 71 | 215.00p | Automatic Execution |
12:20:16 - 13-Mar-26 |
| Sell* | 10 | 215.20p | Ordinary |
12:01:50 - 13-Mar-26 |
| Sell* | 811 | 215.20p | Ordinary |
11:53:36 - 13-Mar-26 |
| Sell* | 2,500 | 215.32p | Ordinary |
11:40:47 - 13-Mar-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 11th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 9th Mar 2026 9:30 am | RNS | Update on Licensed Oncology Product in China |
| 6th Mar 2026 8:30 am | RNS | Directorate change |
| 5th Mar 2026 1:00 pm | RNS-R | Publication of Form 20-F |
| 5th Mar 2026 11:00 am | RNS | 2025 Full Year Results and Business Updates |
| 4th Mar 2026 8:30 am | RNS-R | HUTCHMED Initiates Global Trial of ATTC Candidate |
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |